医学
贫血
内科学
血红蛋白
外科
胃肠病学
肾脏疾病
血液透析
临床试验
肾
作者
Huiling Fu,Qiao Huang,Qiong Wu,Changxuan Liu,Li Xu,Wenli Chen
标识
DOI:10.1016/j.xkme.2026.101575
摘要
Renal anemia can have substantial effects on the survival and prognosis of patients with chronic kidney disease (CKD). We report the case of a 48-year-old patient on hemodialysis whose anemia was effectively corrected with roxadustat, with stable hemoglobin levels (140–153 g/L) maintained for 23 months following drug discontinuation. The patient's iron metabolism was found to have a unique and paradoxical pattern, characterized by a selective reduction in serum ferritin levels, whereas other indicators, including transferrin saturation, remained within normal ranges. These findings indicate that roxadustat may have a sustained regulatory effect on erythropoiesis via undetermined long-term mechanisms. However, they also highlight the need for vigilance regarding the potential risk of hemoglobin overshoot. This case, the first of this nature to be documented, emphasizes the importance of dynamically monitoring hemoglobin levels and iron metabolic parameters during individualized therapy. These findings provide a new perspective for optimizing management strategies for treating renal anemia, and the molecular mechanisms underlying the persistent efficacy observed after drug withdrawal accordingly warrant further in-depth investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI